Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories announced a successful conclusion to the USFDA’s Good Manufacturing Practice (GMP) inspection at its R&D center in Hyderabad, with the inspection closing without any observations. This positive outcome is expected to bolster investor confidence in the company’s compliance and operational standards.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com